US Patent

US8536130 — Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain

Method of Use · Assigned to Gruenenthal GmbH · Expires 2028-09-22 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of 1-phenyl-3-dimethylaminopropane compounds, such as tapentadol hydrochloride, for treating neuropathic pain.

USPTO Abstract

Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.

Drugs covered by this patent

tapentadol-hydrochloride (TAPENTADOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1276`	—	tapentadol-hydrochloride
`U-1276`	—	tapentadol-hydrochloride
`U-1276`	—	tapentadol-hydrochloride
`U-1276`	—	tapentadol-hydrochloride
`U-1276`	—	tapentadol-hydrochloride

Patent Metadata

Patent number: US8536130
Jurisdiction: US
Classification: Method of Use
Expires: 2028-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Gruenenthal GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.